Short answer
Protara Therapeutics, Inc. (TARA) filed its Q2 2026 10-Q quarterly report on Aug 11, 2026 for the quarter ended Jun 30, 2026.
Q2 2026 key financials · XBRL
- Net income
- −$22M
- −44.8% YoY · −21.9% QoQ
- EPS (diluted)
- −$0.36
- +0.0% YoY · −16.1% QoQ
Source: XBRL data from the Protara Therapeutics, Inc. (TARA) Q2 2026 10-Q on SEC EDGAR. USD.
Protara Therapeutics, Inc. Q2 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Revenue $0, unchanged from $0 YoY; no revenues since inception
- Net loss $21.7M vs $15.0M YoY; operating margin not applicable
- Highest R&D spend TARA-002 NMIBC $6.8M vs $4.9M; lowest TARA-002 LMs $0.9M vs $0.5M
- Cash and securities $161.9M vs $197.9M at December 31, 2025; operating cash use $36.7M
- Near-term milestones: registrational NMIBC enrollment completion Q4 2026; IV Choline interim results Q4 2026; STARBORN-1 completion Q4 2026
Risk Factors
- No material risk-factor changes from the December 31, 2025 Form 10-K
- Clinical development risk carried forward for TARA-002 in NMIBC and LM indications
- Regulatory approval risk carried forward for investigational product candidates
- Competitive biotechnology market risk carried forward amid competing therapies and development programs
- Equity financing and dilution risk from conversion of approximately 2,652 preferred shares into 2,653,351 common shares
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Protara Therapeutics, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.